Outcomes
VIRUS, PLAQUE
The primary outcome measure was vaccine (humoral) immunogenicity at 28 days after the third dose of either BNT162b2 or CoronaVac, measured as geometric mean titre (GMT) of SARS-CoV-2 serum neutralising antibodies against the vaccine strain (ancestral virus) using a plaque reduction neutralisation test (PRNT